ArticleJournal of molecular neuroscience : MN2010
Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia--a case-control study.
Article in Journal of molecular neuroscience : MN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label Trial of Tocilizumab in Schizophrenia
A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Pooled it
- Trial
- Evaluating Associations between Average Pain Intensity and Genetic Variation in People with Sickle Cell Disease: An Exploratory Study.Pain management nursing : official journal of the American Society of Pain Management Nurses · 2023Article
- Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia.Pharmacological reports : PR · 2021Review
- Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment.Frontiers in psychiatry · 2021Review
- Increased Dietary Inflammatory Index Is Associated with Schizophrenia: Results of a Case-Control Study from Bahrain.Nutrients · 2019Article
- Symptom Science: Advocating for Inclusion of Functional Genetic Polymorphisms.Biological research for nursing · 2019Review
- Pro-inflammatory cytokines and their epistatic interactions in genetic susceptibility to schizophrenia.Journal of neuroinflammation · 2016Article
- Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia.Journal of psychiatry & neuroscience : JPN · 2016Article
- Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in Indian populations.Molecular genetics & genomic medicine · 2016Article
- Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation.European archives of psychiatry and clinical neuroscience · 2015Article
- Genetic Variants of Interleukin-10 Gene Promoter are Associated with Schizophrenia in Saudi Patients: A Case-Control Study.North American journal of medical sciences · 2014Article
- Neuroimmunological aberrations and cerebral asymmetry abnormalities in schizophrenia: select perspectives on pathogenesis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2014Review
- Genetic variants in transforming growth factor-β gene (TGFB1) affect susceptibility to schizophrenia.Molecular biology reports · 2013Article
- Article
- Cryoglobulins as potential triggers of inflammation in schizophrenia.Schizophrenia research and treatment · 2013Article
- PRENATAL INFECTION, MATERNAL IMMUNE ACTIVATION, AND RISK FOR SCHIZOPHRENIA.Translational neuroscience · 2012Article
- Immune system gene dysregulation in autism and schizophrenia.Developmental neurobiology · 2012Review
- The Long and the Short of it: Gene and Environment Interactions During Early Cortical Development and Consequences for Long-Term Neurological Disease.Frontiers in psychiatry · 2012Article
- ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study.BMC medical genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a multifactorial disease with changes in immunological system. Such changes are the result of cytokine-level disturbances connected with cytokine gene polymorphisms. However, research about cytokine gene polymorphisms in schizophrenia has been surprisingly limited and ambiguous. The aim of the study was to identify whether polymorphisms of interleukin (IL)-6 and IL-10 are risk factors for the development of paranoid schizophrenia in case-control study. IL-6 (-174G/C; rs 1800795) and IL-10 (-1082G/A; rs 1800896) promoter polymorphisms in patients with paranoid schizophrenia and healthy individuals were genotyped using polymerase chain reaction-restriction fragment length polymorphism method. Differences in IL-6 and IL-10 promoter haplotypes may play an important role in determining the transcription level for IL-6 and IL-10 genes in schizophrenic patients. The presence of allele C at position -174 of IL-6 promoter sequence may correlate with increasing risk of paranoid schizophrenia in the Polish population, but research on a broadened group of people is needed. The presence of allele G at position -1082 of IL-10 promoter sequence correlates with increasing risk of paranoid schizophrenia in the Polish population. The coexistence of genotype GG at position -1082 of IL-10 promoter sequence and genotype GC at position -174 of IL-6 promoter sequence correlates with increasing risk of paranoid schizophrenia in the Polish population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.